Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Neurofibromatosis type 1 (NF1) is characterized by loss-of-function mutations in the NF1 gene, leading to increased RAS-MEK-ERK signaling and tumor formation.
• MEK inhibitors (MEKi) show efficacy in shrinking neurofibromas but do not eradicate tumor cells, leading to regrowth upon withdrawal.
• Enhancing phosphatase activity, specifically Protein Phosphatase 2A (PP2A), presents an alternative therapeutic strategy.

Purpose of the Study:

• To investigate the role of PP2A phosphatase in NF1 tumorigenesis.
• To evaluate FTY720, a PP2A activator, as a potential therapeutic agent for NF1.

Main Methods:

• Analysis of PP2A subunit expression and activity in NF1 neurofibroma and Schwann cells.
• In vitro assessment of FTY720's effects on neurofibroma Schwann cell progenitor proliferation, sphere formation, and apoptosis.
• In vivo evaluation of FTY720, alone and in combination with MEKi, in a murine model of NF1.

Main Results:

• Reduced expression and enzymatic activity of PP2A A and C subunits were observed in NF1 neurofibroma cells.
• FTY720 inhibited tumor sphere formation, suppressed proliferation, and induced apoptosis in NF1-derived Schwann cells.
• FTY720 treatment, alone or combined with MEKi, significantly reduced tumor burden in an NF1 mouse model.

Conclusions:

• Dysregulation of PP2A is implicated in NF1 tumorigenesis.
• FTY720 demonstrates therapeutic potential for NF1 by restoring PP2A activity and inhibiting tumor growth.
• FTY720 represents a promising novel therapeutic strategy for NF1, potentially in combination with existing treatments.